Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.
NCT ID: NCT06726850
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
129 participants
INTERVENTIONAL
2022-09-02
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
Participants will receive multiple doses of placebo matching GS1-144 tablet for 12 consecutive weeks.
Placebo
In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
GS1-144 tablet
Participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks.
GS1-144
In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
GS1-144
In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females meeting 1 of the following criteria of menopause at screening visit: spontaneous amenorrhea for ≥ 12 consecutive months, spontaneous amenorrhea for ≥ 6 consecutive months with serum follicle-stimulating hormone (FSH) \> 40 IU/L, or 6 weeks past a postsurgical bilateral oophorectomy with or without hysterectomy;
* Participants who are seeking treatment or relief for VMS and meet the criteria for moderate to severe VMS symptoms: during the 7 consecutive days prior to randomization, participants must have a minimum average of 7 episodes of moderate to severe VMS symptoms per day;
* For females with uterus: endometrial thickness ≤ 4mm as shown by TVU at screening, or \> 4mm without atypical hyperplasia or carcinogenesis of the endometrium from the subsequent biopsy results (If the biopsy sample is insufficient or can't be obtained, it is considered normal and meets this inclusion criterion);
* Volunteered to sign ICF and be able to understand and comply with the requirements of this study.
Exclusion Criteria
* Thyroid or parathyroid-related hormones abnormalites with clinical significance at screening or baseline;
* Confirmed moderate to severe liver fatty at screening or baseline;
* Any surgical or medical conditions that may significantly affect the absorption, distribution, metabolism, and/or excretion of the drug, such as a history of gastrointestinal surgery (gastrectomy, gastroenterostomy, enterectomy, etc.), urinary tract obstruction, or dysuria;
* Current or prior history of malignancy (except for malignancies and basal cell carcinoma that have not received any antineoplastic treatment within 5 years prior to screening visit, or have currently recovered or have no risk of relapse during this study as assessed by the investigator);
* Abnormal uterine bleeding with clinical significance during screening period or baseline period;
* Participants who have attempted suicide within the last 1 year or are currently at risk of impulsive behavior or suicide;
* Participants with a history of severe allergy to investigational products or any of their excipients or with allergic constitution (e.g., being allergic to two or more drugs or foods);
* Participants who have positive serology results of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab) or syphilis;Abnormalities in vital signs during the screening period or baseline period, e.g., resting pulse rate \< 55/min or \> 105/min; systolic blood pressure \< 90 mmHg or ≥ 160 mmHg; diastolic blood pressure \< 60 mmHg or ≥ 100 mmHg, that upon evaluation by the investigator may interfere with this clinical study;
* BI-RADS (Breast Imaging Reporting and Data System) Category ≥4 on breast ultrasound within 6 months prior to randomization;
* Participants who have positive pregnancy test during screening or baseline period.
* 12-lead electrocardiography (ECG) abnormalities during screening period or baseline period, e.g., heart rate-corrected QT interval QTcF absolute value \>470 ms (Fridericia's formula: QTcF=QT/RR0.33) that upon evaluation by the investigator may interfere with this clinical study;
* Abnormalities in laboratory tests during screening period or baseline period, e.g., alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2×upper limit of normal (ULN), or total bilirubin (TBIL) \>1.5×ULN, that upon evaluation by the investigator may interfere with this clinical study;
* Creatinine \>1.5×ULN or estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 based on modification of diet in renal disease (MDRD) during screening period or baseline period;
* The participant has used or is using prohibited medications/therapies (moderate or strong CYP1A2 inhibitors, hormone replacement therapy or any VMS therapeutic agents \[prescription, non-prescription or herbal medicines\]) at screening and is unwilling to discontinue and wash out such medications throughout the study (see Section 6.9 for the washout intervals for prohibited concomitant medications and prior medications);
* Having participated in any other clinical trial within 3 months or any clinical study of fezolinetant or other treatments for VMS (except for participants who have not received any investigational product) within 1 year prior to screening, or planning to participate in any other clinical trial;
* Current or prior history of drug use, drug abuse or alcohol abuse;
* Any other conditions that are unsuitable for participating in this study in the opinion of the investigator.
40 Years
64 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changchun GeneScience Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GenSci074-201
Identifier Type: -
Identifier Source: org_study_id